Relay Therapeutics, Inc. Common Stock

Relay Therapeutics' 16.83% short interest stands unusually high for a biotech with $2.4B market cap, signaling meaningful skepticism despite the stock trading 46.9 RSI—right at neutral momentum. The absence of a P/E ratio indicates the company remains unprofitable, typical for clinical-stage therapeutics where revenue hasn't yet materialized. Trading below its 52-week high with balanced technical conditions suggests the market is pricing in execution risk heavily. The elevated short position creates mild squeeze vulnerability if clinical progress accelerates unexpectedly, but fundamentals appear to justify caution given the burn rate inherent in drug development stages without profitable operations